Cargando…
Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT
The sensitivity to 5-fluorouracil (5-FU) has been reported to be associated with target molecule thymidylate synthase (TS), fluoropyrimidine-metabolising enzymes such as orotate phosphoribosyltransferase (OPRT), and dihydropyrimidine dehydrogenase (DPD). We performed an immunohistochemical study on...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360692/ https://www.ncbi.nlm.nih.gov/pubmed/16880781 http://dx.doi.org/10.1038/sj.bjc.6603297 |
_version_ | 1782153111812440064 |
---|---|
author | Nakano, J Huang, C Liu, D Masuya, D Nakashima, T Yokomise, H Ueno, M Wada, H Fukushima, M |
author_facet | Nakano, J Huang, C Liu, D Masuya, D Nakashima, T Yokomise, H Ueno, M Wada, H Fukushima, M |
author_sort | Nakano, J |
collection | PubMed |
description | The sensitivity to 5-fluorouracil (5-FU) has been reported to be associated with target molecule thymidylate synthase (TS), fluoropyrimidine-metabolising enzymes such as orotate phosphoribosyltransferase (OPRT), and dihydropyrimidine dehydrogenase (DPD). We performed an immunohistochemical study on the clinical significance of TS, OPRT, and DPD expression using 151 resected non-small-cell lung cancer (NSCLC) patients postoperatively treated with a combination of tegafur and uracil (UFT). Eighty-two carcinomas were TS-positive, 105 carcinomas were OPRT-positive, 68 carcinomas were DPD-positive. No correlation was observed in the HSCORE between the TS and OPRT expression (r=0.203), between the TS and DPD expression (r=0.098), or between the OPRT and DPD expression (r=0.074). Regarding the survival of NSCLC patients treated with UFT, the 5-year survival rate of patients with TS-negative tumours was significantly higher than that with TS-positive tumours (P=0.0133). The 5-year survival rate of patients with OPRT-positive stage II to III tumours was significantly higher than that with OPRT-negative stage II to III tumours (P=0.0145). In addition, the 5-year survival rate of patients with DPD-negative tumours was also significantly higher than that with DPD-positive tumours (P=0.0004). A Cox multivariate regression analysis revealed the TS status (hazard ratio 2.663; P=0.0003), OPRT status (hazard ratio 2.543; P=0.0005), and DPD status (hazard ratio 2.840; P<0.0001) to all be significant prognostic factors for the survival of resected NSCLC patients postoperatively treated with UFT. |
format | Text |
id | pubmed-2360692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23606922009-09-10 Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT Nakano, J Huang, C Liu, D Masuya, D Nakashima, T Yokomise, H Ueno, M Wada, H Fukushima, M Br J Cancer Molecular Diagnostics The sensitivity to 5-fluorouracil (5-FU) has been reported to be associated with target molecule thymidylate synthase (TS), fluoropyrimidine-metabolising enzymes such as orotate phosphoribosyltransferase (OPRT), and dihydropyrimidine dehydrogenase (DPD). We performed an immunohistochemical study on the clinical significance of TS, OPRT, and DPD expression using 151 resected non-small-cell lung cancer (NSCLC) patients postoperatively treated with a combination of tegafur and uracil (UFT). Eighty-two carcinomas were TS-positive, 105 carcinomas were OPRT-positive, 68 carcinomas were DPD-positive. No correlation was observed in the HSCORE between the TS and OPRT expression (r=0.203), between the TS and DPD expression (r=0.098), or between the OPRT and DPD expression (r=0.074). Regarding the survival of NSCLC patients treated with UFT, the 5-year survival rate of patients with TS-negative tumours was significantly higher than that with TS-positive tumours (P=0.0133). The 5-year survival rate of patients with OPRT-positive stage II to III tumours was significantly higher than that with OPRT-negative stage II to III tumours (P=0.0145). In addition, the 5-year survival rate of patients with DPD-negative tumours was also significantly higher than that with DPD-positive tumours (P=0.0004). A Cox multivariate regression analysis revealed the TS status (hazard ratio 2.663; P=0.0003), OPRT status (hazard ratio 2.543; P=0.0005), and DPD status (hazard ratio 2.840; P<0.0001) to all be significant prognostic factors for the survival of resected NSCLC patients postoperatively treated with UFT. Nature Publishing Group 2006-09-04 2006-08-01 /pmc/articles/PMC2360692/ /pubmed/16880781 http://dx.doi.org/10.1038/sj.bjc.6603297 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Nakano, J Huang, C Liu, D Masuya, D Nakashima, T Yokomise, H Ueno, M Wada, H Fukushima, M Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT |
title | Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT |
title_full | Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT |
title_fullStr | Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT |
title_full_unstemmed | Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT |
title_short | Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT |
title_sort | evaluations of biomarkers associated with 5-fu sensitivity for non-small-cell lung cancer patients postoperatively treated with uft |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360692/ https://www.ncbi.nlm.nih.gov/pubmed/16880781 http://dx.doi.org/10.1038/sj.bjc.6603297 |
work_keys_str_mv | AT nakanoj evaluationsofbiomarkersassociatedwith5fusensitivityfornonsmallcelllungcancerpatientspostoperativelytreatedwithuft AT huangc evaluationsofbiomarkersassociatedwith5fusensitivityfornonsmallcelllungcancerpatientspostoperativelytreatedwithuft AT liud evaluationsofbiomarkersassociatedwith5fusensitivityfornonsmallcelllungcancerpatientspostoperativelytreatedwithuft AT masuyad evaluationsofbiomarkersassociatedwith5fusensitivityfornonsmallcelllungcancerpatientspostoperativelytreatedwithuft AT nakashimat evaluationsofbiomarkersassociatedwith5fusensitivityfornonsmallcelllungcancerpatientspostoperativelytreatedwithuft AT yokomiseh evaluationsofbiomarkersassociatedwith5fusensitivityfornonsmallcelllungcancerpatientspostoperativelytreatedwithuft AT uenom evaluationsofbiomarkersassociatedwith5fusensitivityfornonsmallcelllungcancerpatientspostoperativelytreatedwithuft AT wadah evaluationsofbiomarkersassociatedwith5fusensitivityfornonsmallcelllungcancerpatientspostoperativelytreatedwithuft AT fukushimam evaluationsofbiomarkersassociatedwith5fusensitivityfornonsmallcelllungcancerpatientspostoperativelytreatedwithuft |